None listed
Conditions
Interventions
Intervention1: Skin Renew Peptide Retinol Serum: Test Product: Skin Renew Peptide Retinol Serum
Dose: gently massage approx. 8 drops serum over the face with fingers in outward manner two times a day.
Sponsors
Honasa Consumer Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1) Gender: Non-pregnant, non-lactating female aged between 25 to 45. 2) Subjects willing to give written informed consent 3) Women of childbearing potential must have a negative urine pregnancy test prior to study entry. 4) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 5) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.
Exclusion criteria
Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 3. Have open sores or open lesions in the treatment area(s). 4. Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 5. Have participated in any interventional clinical trial in the previous 30 days. 6. Have a known sensitivity to any of the constituents of the test product. 7. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. 8. Have a history of alcohol or illegal drug or substance abuse, or suspected alcohol or illegal drug or substance abuse in the past 2 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in dark spot reduction, an evens out tone, Skin elasticity and firmness pigmentation and hyperpigmentationTimepoint: Day 0, Day 14 and Day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety and tolerabilityTimepoint: Day 0, Day 14 and Day 28 | — |
Countries
India
Contacts
Public ContactPuneet Mittal
CCFT Laboratories
Outcome results
None listed